UNSPSC 51312408: Tripelennamine citrate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H21N3.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30OC46A3J9, chemically known as 1,2-ethanediamine, n,n-dimethyl-n-(phenylmethyl)-n-2-pyridinyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) but more generally known as tripelennamine citrate, which bears US NIH Compound Identifier 197066.

UNSPSC 51312408 Tripelennamine citrate is a Commodity code that nominally identifies a specific antihistamine active pharmaceutical ingredient, but recent state and local procurement activity under this code shows no direct alignment with the chemical compound itself. Instead, the code appears in solicitations for broader pharmaceutical and drug-management products and services—including naloxone distribution systems, generic multi-source pharmaceuticals, and prescription management programs—suggesting either misclassification in individual procurement notices or use of the code as a catch-all placeholder within pharmacy procurement workflows. State and local governments purchasing under this code span county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. Seminole County, Florida, and the Texas Health and Human Services Commission and Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the issuing bodies in recent opportunities, indicating activity at county, state, and multi-state cooperative levels.

Recent procurement activity appears concentrated in Florida, Texas, and Minnesota. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor information on direct-to-manufacturer prescription fulfillment capabilities outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP, administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesalers, with proposals due March 26, 2026, and contract effectiveness targeted for July 1, 2026. These solicitations indicate state and local focus on cost-effective pharmaceutical sourcing, direct manufacturer relationships, and centralized procurement for health and human services delivery.